Dricenta Weekly Updates

China’s CDE granted BTD to iza-bren (EGFR×HER3 bsADC) for 2L BTC, marking the asset’s 9th CDE BTD indication

FDA clears IND for IM-1340, a potential FIC transport-receptor ADC with proprietary TOP1 payload, advancing toward Ph1 FIH in Q4’2026

NMPA clinical trial approval for BL-M12D1 (undisclosed ADC) in R/R hematologic malignancies, leveraging iza-bren’s linker-payload platform

Registered global Ph3 TREVI-OC-02 evaluating torvutatug samrotecan (FRα ADC) + bevacizumab (VEGF mAb) as 1L maintenance in HRD− OC, signalling a strategy to move the FRα ADC earlier into 1L maintenance and address the large HRD− population

Enrolled the first pt in a Ph3 of T-Bren (HER2 ADC) in HER2+ PROC, broadening late-line gynecologic oncology positioning

FPD in registrational TEMPO-1 trial, evaluating CRB-701 (Nectin-4 ADC) in 2L+ OPSCC; targeting potential accelerated approval

Initiated the Ph1b BActinium-2 trial of AKY-2519 (B7-H3 radioconjugate), in pts with NSCLC & other B7-H3+ solid tumors, expanding clinical development beyond mCRPC

Will unveil first comparative preclinical data for KNP-701 (EGFRxc-MET bsADC) at World ADC San Diego 2026, highlighting differentiated antibody design and BD potential

Doses first patient in global Ph1/2 TJ102, advancing FRα×CDH6 bispecific dual-payload ADC against ovarian cancer heterogeneity and resistance.

Initiates global Ph1 FIC HMPL-A830 (KRAS inhibitor–EGFR ATTC), advancing GSK-partnered targeted payload delivery in KRAS tumors

LCB43 (BCMA ADC) outperformed Blenrep biosimilar preclinically; IND filing targeted within 2026.

FPD in FIH Ph1b/2 evaluating XYA02 (MUC1-C ADC) in R/R solid tumors, transitioning XYone into a clinical-stage company, with existing FDA ODDs in PDAC & GC supporting a broader MUC1-C development strategy

Completes R&D Exatecan batches, establishing a European payload source to diversify ADC supply and streamline payload-to-drug-substance manufacturing.

Invested €70M to expand St. Louis ADC manufacturing by 3,200 m², strengthening U.S. capacity for complex bioconjugates and commercialization

Advances Accum®-enhanced ADC partnerships and radiotherapeutics, strengthening scientific capabilities and sharpening strategic development priorities; participating in World ADC San Diego 2026

Licensed Abion’s interferon-beta immunocytokine platform, securing global rights across five targets for next-gen iADCs

Partnered to leverage AI-designed de novo antibodies and ADC expertise, targeting novel antigens beyond existing therapies

Announced achievement of a $7M research milestone from Pfizer under their strategic collaboration to discover & develop DACs, combining antibody selectivity with targeted protein degradation.

$2B strategic equity investment + clinical collaboration to evaluate Sone-Ve (CLDN18.2 ADC) + ivonescimab (PD-1xVEGF bsAb) in GC and Datroway (TROP2 DXd ADC) + ivonescimab across tumors, beginning with Ph3 1L TNBC, expanding ADC-IO combination strategy (Source 1, Source 2)